An automated, highly sensitive LC-MS/MS assay for the quantification of the opiate antagonist naltrexone and its major metabolite 6β-naltrexol in dog and human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 874, Issue 1-2, 2008, Pages 33-41

  Clavijo, Claudia ^a   Bendrick Peart, Jamie ^a,b   Zhang, Yan Ling ^a   Johnson, Gillian ^a   Gasparic, Antje ^c   Christians, Uwe ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Eurofins Medinet Inc   (Germany)

^c Elbion AG   (Germany)

Author keywords

6 Naltrexol; Column switching; Dog plasma; Human plasma; LC MS MS; Naltrexone

Indexed keywords

CHEMICAL SENSORS; PHARMACOKINETICS; PLASMA (HUMAN); PLASMAS;

COLUMN SWITCHING; DOG PLASMA; HUMAN PLASMA; LC-MS/MS; NALTREXONE;

DRUG PRODUCTS;

NALTREXOL; NALTREXONE; SINOMENINE;

ARTICLE; AUTOMATION; BIOASSAY; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY;

ANIMALS; CHROMATOGRAPHY, LIQUID; DOGS; HUMANS; MOLECULAR STRUCTURE; NALTREXONE; NARCOTIC ANTAGONISTS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

ANIMALIA; CANIS FAMILIARIS;

EID: 53249101305     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.08.021     Document Type: Article

References (19)

1. Ginzburg H.M., and MacDonald M.G. Med. Toxicol. 2 (1987) 83
2. Martin W.R., Jasinski D.R., and Mansky P.A. Arch. Gen. Psychiatry 28 (1973) 784
3. Swift R.M. N. Engl. J. Med. 340 (1999) 1482
4. Grant J.E., and Kim S.W. Ann. Clin. Psychiatry 3 (2002) 155
5. Foster J., Brewer C., and Steele T. Addict. Biol. 2 (2003) 211
6. Gonzalez J.P., and Brogden R.N. Drugs 35 (1988) 192
7. Slawson M.H., Chen M., Moody D., Comer S.D., Nuwayser E.S., Fang W.B., and Fotz R.L. J. Anal. Toxicol. 8 (2007) 453
8. Kintz P., Mangin P., Lugnier A.A., and Chaumont A.J. Z. Rechtsmed. 1 (1989) 57
9. Davidson A.F., Emm T.A., and Pieniaszek Jr. H.J. J. Pharm. Biomed. Anal. 12 (1996) 1717
10. Kambia K., Bah S., Dine T., Azar R., Odou P., Gressier B., Luycky M., Brunet C., Ballester L., Cazin M., and Cazin J.C. Biomed. Chromatogr. 3 (2000) 151
11. Valiveti S., Nalluri B.N., Hammell D.C., Paudeli K.S., and Stinchcomb A.L. J. Chromatogr. 2 (2004) 259
12. Chan C.F., Chiswell G.M., Bencini R., Hackett L.P., Dusci L.J., and Ilett K.F. J. Chromatogr. 1 (2001) 85
13. Lee M.C., Wagner H.N., Tanada S., Frost J.J., Bice A.N., and Dannals R.F. J. Nucl. Med. 29 (1988) 1207
14. Schuh K.J., Walsh S.L., and Stitzer M.L. Psychopharmacology 145 (1999) 162
15. Kranzler H.R., Modesto-Lowe V., and Nuwayser E.S. Alcohol Clin. Exp. Res. 22 (1988) 1074
16. Iyer S.S., Kellogg G.E., and Karnes H.T. J. Chromatogr. Sci. 45 (2007) 694
17. Zhang Y.L., Bendrick-Peart J., Strom T., Haschke M., and Christians U. Ther. Drug Monit. 27 (2005) 770
18. Center for Drug Evaluation and Research (CDER), Guidance for Industry, Bioanalytical Method Validation, 2001 (www.fda.gov/cder/guidance/4252fnl.htm, last accessed October 14, 2007).
19. Müller C., Schäfer P., Störtzel M., Vogt S., and Weinmann W. J. Chromatogr. B 773 (2002) 47